Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 4/13/26 | Revolution Medicines (RVMD) | daraxonrasib for Pancreatic Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/11/26 | Viatris (VTRS) | Ryzumvi for Presbyopia | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/7/26 | NervGen Pharma (NGEN) | NVG-291 for Spinal Cord Injury (SCI) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/2/26 | Immunovant (IMVT) | batoclimab for Thyroid Eye Disease (TED) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/2/26 | AstraZeneca (AZN) | Imfinzi for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |